US will be world's premier pharmacy drug store and medical manufacturer: Trump

cnbctv18 | May 21, 2020

The COVID-19 pandemic has proven once and for all that to be a strong nation, America must be a manufacturing nation, US President Donald Trump said on Thursday declaring the goal of making his country the world's premier pharmacy, drug store, and medical manufacturer. "The global pandemic has proven once and for all that to be a strong nation, America must be a manufacturing nation.... Today, I'm declaring a simple but vital national goal. The United States will be the world's premier pharmacy, drug store, and medical manufacturer. We are bringing our medicines back, he said in Michigan. The United States, he said, must produce critical equipment, supplies, pharmaceuticals, technologies for itself. We cannot rely on foreign nations to take care of us, especially in times of difficulty, he said. In previous decades, he alleged, politicians shipped away jobs, outsourced supply chains and offshored industries. They sent them abroad and we're bringing them back and we've been doing that long before this crisis. We're bringing them back. That's why we have so many plants being built all over the United States that make a beautiful product called cars. Bringing them back. You see it, he said.

Spotlight

According to the National Assessment of Adult Literacy, only 12 percent of adults in the U.S. have proficient health literacy. In terms of numbers, that is nine out of ten adults who lack the skills needed to manage their health and prevent disease. Low literacy has been linked to poor health outcomes such as higher rates of hospitalization and less frequent use of preventive services, which leads to higher healthcare costs. This is especially troubling for individuals over the age of 65 because they have low health literacy, live on a fixed budget and Medicare doesn’t pay for all the costs.

Spotlight

According to the National Assessment of Adult Literacy, only 12 percent of adults in the U.S. have proficient health literacy. In terms of numbers, that is nine out of ten adults who lack the skills needed to manage their health and prevent disease. Low literacy has been linked to poor health outcomes such as higher rates of hospitalization and less frequent use of preventive services, which leads to higher healthcare costs. This is especially troubling for individuals over the age of 65 because they have low health literacy, live on a fixed budget and Medicare doesn’t pay for all the costs.

Related News

PHARMACY MARKET

GluCare.Health Partners with Novo Nordisk for Innovative Weight Management Patient Program

Glucare.Health and NovoNordisk: | June 09, 2022

GluCare.Health, one of the Middle East's leading health tech startups, has partnered with global pharmaceutical company Novo Nordisk, market leader in Diabetes & Obesity, to introduce a blueprint for the future of healthcare. The partnership will see a 150-patient weight management pilot program that will combine new digital bio-markers, using wearable technology and devices for continuous data monitoring, with existing therapeutics. It introduces the Middle East's first value-based reimbursement model, and will be the first relationship of its kind for Novo Nordisk globally. This innovative partnership will put accountability for outcomes vs. costs on the provider, rather than on the insurers or patients. The 6-month program, which begins in September, is open to people with obesity who meet certain criteria. Patients will receive an unparalleled level of in-patient and data-driven remote care, with a multidisciplinary clinic team having continuous access to all patient data through an intelligent analytical platform. If patients do not lose at least 10% of their body weight by the end of the program, GluCare.Health and Novo Nordisk will cover all or a portion of the cost under the value-based reimbursement pilot. GluCare.Health is also committed to transparency when it comes to reporting results of the program. With one in three adults affected by obesity in the UAE[1], GluCare.Health's Co-Founder and Managing Director, Dr. Ihsan AlMarzooqi, says that the blueprint for care has the potential to not only save many lives but the UAE economy billions of dollars in costs and lost productivity. "When patients with chronic conditions are not supported properly, it can have a devastating impact on those individuals and their families. Additionally, the cost of treating the health consequences of obesity to the UAE economy alone is approximately $3.6 billion annually[2]. Traditional models of care remain woefully limited when it comes to outcomes. This partnership allows us to embed Novo Nordisk's advanced therapeutics into a companion platform like GluCare.Health, which enhances its efficacy dramatically." About Glucare.Health The first hybrid Digital Therapeutics (DTx)+Human vertically integrated diabetes platform of its kind in the world, GluCare.Health is reinventing metabolic care and transforming lives. Conceptualized in the UAE and opening the doors to its state-of-the-art 10,000 sq foot Dubai clinic in September 2020, it is the world's first healthcare provider to empower both clinicians and patients through Remote Continuous Data Monitoring as part of its standard model of care, an innovative and highly personalized 'continuous healthcare' approach that provides a comprehensive and real-time view of patients. As part of its unique model, GluCare is also an early adopter of - and the region's first clinic to use - Digital Therapeutics (DTx), combining it with wearable and smart technology, data analytics, unique in-clinic workflows, and a caring and connected expert care team. Applying technology as a humanizing force, GluCare.Health's team partners with patients and their families, giving them the tools, knowledge, and continuous support to live longer, healthier, and more fulfilling lives. About NovoNordisk Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 49,300 people in 80 countries and markets its products in around 170 countries. For more information, visit Novo Nordisk UAE.

Read More

PHARMA TECH

Armata Pharmaceuticals Announces Clearance of IND for Prosthetic Joint Infections

Armata Pharmaceuticals, Inc | August 02, 2022

Armata Pharmaceuticals, Inc. a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the U.S. Food and Drug Administration has cleared Armata's Investigational New Drug application for AP-SA02 in prosthetic joint infection. The company is initiating start-up activities for the Phase 1b/2a trial that will explore the safety, tolerability, and pharmacokinetics of intravenous and intra-articular doses of AP-SA02 as an adjunct to standard of care antibiotics in subjects with PJI. "Prosthetic joint infection is one of the most serious complications of prosthetic joint implantation. Staphylococcus aureus is a dominant pathogen that drives the need for surgical intervention and prolonged courses of antibiotic therapy. The ability of S. aureus to create biofilms that are refractory to standard of care antibiotics highlights the need for a novel therapy. Phage therapy may fill this need for PJI patients as phage have demonstrated the ability to disrupt biofilm and work synergistically with antibiotics." Dr. Mina Pastagia, Armata's Senior Vice President of Clinical Development "Armata is excited to explore AP-PA02 in patients who suffer from complicated joint infections that don't respond adequately to standard of care antibiotics. PJI is a logical extension of our diSArm trial which is targeting complicated S. aureus bacteremia," said Brian Varnum, Chief Executive Officer of Armata. "With this IND approval, Armata now has four active clinical programs. Today marks an important development milestone for Armata and its investors who set a course three years ago to transform phage therapy from a promising new technology to one that is explored in rigorous clinical settings." In addition to evaluating AP-SA02 in PJI and bacteremia due to S. aureus, Armata has advanced AP-PA02 into the Phase 2a component of the SWARM-P.a. study which targets chronic Pseudomonas aeruginosa infections in people with cystic fibrosis (CF). In February, the company gained IND clearance for AP-PA02 in a second indication, non-cystic fibrosis bronchiectasis targeting patients with chronic P. aeruginosa infections in a Phase 2 trial. About Armata Pharmaceuticals, Inc. Armata is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, known as MSD outside of the United States and Canada, Armata is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.

Read More

PHARMACY MARKET

Vipergen and LEO Pharma Partner for DNA Encoded Library (DEL)-Based Drug Discovery for Dermatology Indications

Vipergen | June 20, 2022

Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library technologies, announced a multi-target drug discovery partnership with LEO Pharma focused on novel treatments for dermatology indications. Under the terms of the agreement, Vipergen will apply its high-fidelity DNA-encoded library (DEL) screening technologies, including its new in-living-cell DEL platform, to discover novel small-molecule compounds that bind to selected LEO Pharma targets. LEO Pharma will select hits for potential development into innovative drugs for dermatology applications. LEO Pharma will retain exclusive rights to globally commercialize any products resulting from the collaboration. Financial details of the agreement were not disclosed. "Driving our mission to rapidly bring better treatments to people with skin conditions, we continue to explore ways to discover novel small-molecule compounds for innovative and challenging targets while shortening development timelines. Partnering with Vipergen gives us access to the only technology capable of screening DEL libraries inside living cells, under physiologically relevant conditions. We look forward to a productive partnership." Thorsten Thormann, Vice President of Research & Early Development at LEO Pharma "We are very pleased to partner with LEO Pharma in its mission to develop first-in-class and best-in-class treatments for the millions of patients around the world suffering with psoriasis, eczema, acne, skin infections, and other serious skin conditions," said Nils Hansen, PhD, Chief Executive Officer of Vipergen. "We look forward to applying our full suite of DEL screening technologies to accelerate and advance LEO Pharma's efforts to discover novel, high-quality small molecules for development into innovative new treatments." About Vipergen ApS Vipergen is a world-leading provider of small-molecule drug discovery services based on DNA-encoded library technologies and is the first and only company capable of screening DELs inside a living cell. Vipergen provides its proprietary suite of leading-edge DEL technologies through funded discovery partnerships with leading pharmaceutical and biotechnology companies, including top pharmaceutical companies in the U.S., EU, and Japan.

Read More